Midatech Bets on Bioasis Merger For Survival
UK Firm Been Through Turbulent Times
Executive Summary
With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.
You may also be interested in...
Finance Watch: Signs Of Life? A Small Offering, Three New Filings And Galderma Hints At An IPO
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.
Back From The Dead Biodexa Makes Bid For VarianBio
Having just avoided going into administration, the firm formerly known as Midatech has pivoted its business model from a drug delivery company to a therapeutics player and has hit the acquisition trail.
Deal Watch: Merck KGaA Teams Up With Mersana On STING Agonist ADCs
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.